<?xml version="1.0" encoding="UTF-8"?>
<p>In the intensive pathway there were no significant differences at any time point between treatment with CVAD and CTD with respect to Pain and Global Health Status/Quality of Life (Fig 
 <xref rid="bjh15459-fig-0002" ref-type="fig">2</xref>A). However, there were small significant differences in favour of CTD for Fatigue at 3 months with a persistent trend for benefit at 6 and 12 months (Fatigue lower with CTD, 3 months: −4·02 [95% confidence interval (CI) −7·43, −0·61], 
 <italic>P</italic> = 0·02; 6 months: −2·06 [95% CI −6·72, 4·48], 
 <italic>P</italic> = 0·39; 12 months: −3·63 [95% CI −8·51, 1·26], 
 <italic>P</italic> = 0·15, Fig 
 <xref rid="bjh15459-fig-0002" ref-type="fig">2</xref>A) and Physical Functioning at 12 months after small non‐significant benefits at 3 and 6 months (Physical Functioning higher with CTD, 3 months: 0·83 [95% CI −2·37, 4·04], 
 <italic>P</italic> = 0·61; 6 months: 0·82 [95% CI −2·47, 4·10], 
 <italic>P</italic> = 0·63; 12 months: 4·49 [95% CI 0·22, 8·76], 
 <italic>P</italic> = 0·04, Fig 
 <xref rid="bjh15459-fig-0002" ref-type="fig">2</xref>A).
</p>
